Trial Overview

This Phase 1/2 clinical trial, sponsored by M.D. Anderson Cancer Center, assesses the safety and optimal dosage of olaparib combined with either bitueryth (AZD2014, an mTOR inhibitor) or capivasertib (AZD5363, an AKT inhibitor) in patients with recurrent endometrial cancer, ovarian cancer, and other pelvic malignancies. The study commenced in November 2014 and has now completed enrollment, encompassing multiple cancer types to enhance data collection efficiency.

Mechanism and Synergy

Bitueryth inhibits mTOR signaling, while capivasertib suppresses the AKT pathway. Olaparib is a PARP inhibitor that disrupts DNA damage repair. The combination of these mechanisms is expected to significantly limit the repair capabilities of tumor cells, resulting in a synergistic effect. This combined approach may delay the development of resistance compared to single-agent therapy.

Differentiation from Current Treatment Landscape

Recurrent endometrial and ovarian cancers have traditionally been treated with platinum-based chemotherapy or single-agent chemotherapy, with limited treatment options. While PARP inhibitors alone have shown efficacy in some patients, the overall response rate remains relatively low. This trial aims to enhance tumor suppression compared to existing standard treatments by adding mTOR/AKT pathway inhibition, potentially establishing a new treatment paradigm.

Expected Outcomes and Potential Impact

If the safety profile is favorable and dose optimization is successful, the trial may expand into subsequent Phase 2/3 trials, potentially establishing a new first-line treatment option for patients with recurrent pelvic cancers. This could facilitate partnerships for co-development and licensing agreements, thereby increasing the value of the pipeline. Furthermore, positive clinical data may attract increased investor interest in the combination of mTOR/AKT inhibitors and PARP inhibitors.